Related Experiment Videos
Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro
Abstract:
Many investigations have indicated a functional role for carbonic anhydrase in the mediation of hormone-stimulated bone resorption. These studies depend heavily on the use of heterocyclic sulfonamide inhibitors of carbonic anhydrase. These drugs have effects on many tissues other than bone, and some of these effects confound the interpretation of studies of the role of carbonic acid in bone metabolism. A novel, "bone-targeted" sulfonamide has been produced to obviate these extraosseous effects. This compound (designated WP-1) is the combination of tetracycline and acetazolamide, such that the acetazolamide is not an active inhibitor. Hydrolysis of WP-1 yields an active carbonic anhydrase inhibitor. WP-1 has a marked affinity for bone mineral, allowing deposition of the drug in bone. At a concentration of 10(-5) M, WP-1 attenuates parathyroid hormone stimulated net release of calcium from neonatal rat calvaria in culture. WP-1 is the first member of a class of drugs which may prove useful as pharmacological probes in the study of bone metabolism.
Insights
A novel bone-targeted drug, WP-1, inhibits carbonic anhydrase to study bone resorption. This compound targets bone mineral, reducing confounding extraosseous effects in research on hormone-stimulated bone metabolism.
Area of Science:
- Biochemistry
- Pharmacology
- Bone Biology
Background:
- Carbonic anhydrase plays a role in hormone-stimulated bone resorption.
- Heterocyclic sulfonamides are commonly used inhibitors but cause extraosseous effects.
- These extraosseous effects complicate the study of bone metabolism.
Purpose of the Study:
- To develop a novel, bone-targeted carbonic anhydrase inhibitor to overcome limitations of existing drugs.
- To investigate the efficacy of WP-1 in attenuating parathyroid hormone-stimulated bone resorption.
- To introduce WP-1 as a potential pharmacological probe for bone metabolism research.
Main Methods:
- Synthesis of a novel bone-targeted sulfonamide (WP-1) by combining tetracycline and acetazolamide.
- WP-1 is designed to release an active inhibitor upon hydrolysis and possess high affinity for bone mineral.
- Assessment of WP-1's effect on parathyroid hormone-stimulated calcium release from neonatal rat calvaria in culture.
Main Results:
- WP-1 demonstrated a marked affinity for bone mineral, enabling drug deposition in bone.
- At 10(-5) M, WP-1 significantly attenuated parathyroid hormone-stimulated net calcium release from neonatal rat calvaria.
- WP-1 effectively reduced hormone-stimulated bone resorption in vitro.
Conclusions:
- WP-1 is the first bone-targeted carbonic anhydrase inhibitor developed.
- WP-1 effectively reduces extraosseous effects, offering a more specific tool for bone research.
- WP-1 represents a promising pharmacological probe for investigating bone metabolism and resorption processes.